The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Open accessAbstract
BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Adherence can be low (48), and prevention of HIV infection, especially among women, has not been demonstrated (47,49).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 999
Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics
Taneva, E., Sinclair, S., Mesquita, P. M. M., Weinrick, B. C., Cameron, S. A., Cheshenko, N., Reagle, K., Frank, B., Srinivasan, S., Fredricks, D. N., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99545 · Cited by 55
Lanham, M., Ridgeway, K., Mireku, M., Nhamo, D., Pillay, D., Murire, M., Stankevitz, K., Kyongo, J. K., Mullick, S., Bhatasara, T., et al. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06978-0 · Cited by 57
Is tenofovir disoproxil fumarate associated with weight loss?
Shah, S., Pilkington, V., & Hill, A. (2021) · AIDS · doi:10.1097/qad.0000000000003083 · Cited by 58
HIV prevention: better choice for better coverage
Bekker, L., Pike, C., & Hillier, S. L. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25872 · Cited by 55
Women want Pre-Exposure Prophylaxis but are Advised Against it by Their HIV-positive Counterparts
Goparaju, L., Experton, L. S., & Praschan, N. C. (2015) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000522 · Cited by 57
Designing and Developing Suppository Formulations for anti-HIV Drug Delivery
Ham, A. S., & Buckheit, R. W. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0056 · Cited by 55
Atujuna, M., Newman, P. A., Wallace, M., Eluhu, M., Rubincam, C., Brown, B. B., & Bekker, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191251 · Cited by 57
Mitchell, J. T., LeGrand, S., Hightow‐Weidman, L., McKellar, M., Kashuba, A. D. M., Cottrell, M. L., McLaurin, T., Satapathy, G., & McClernon, F. J. (2018) · JMIR mhealth and uhealth · doi:10.2196/10456 · Cited by 54
Pintye, J. C., Drake, A. L., Begnel, E. R., Kinuthia, J., Abuna, F., Lagat, H., Dettinger, J. C., Wagner, A. D., Thirumurthy, H., Mugwanya, K. K., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002211 · Cited by 55
Pons-Faudoa, F. P., Sizovs, A., Trani, N. D., Paez‐Mayorga, J., Bruno, G., Rhudy, J. R., Manohar, M., Gwenden, K. N., Martini, C., Chua, C. Y. X., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.037 · Cited by 55
Planning for HIV preexposure prophylaxis introduction
Delany‐Moretlwe, S., Mullick, S., Eakle, R., & Rees, H. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000221 · Cited by 56
Potent Inhibition of HIV-1 Replication in Resting CD4 T Cells by Resveratrol and Pterostilbene
Chan, C. N., Trinité, B., & Levy, D. N. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00408-17 · Cited by 53
Heffron, R. A., McClelland, R. S., Balkus, J. E., Celum, C., Cohen, C. R., Mugo, N., Bukusi, E. A., Donnell, D. J., Lingappa, J. R., Kiarie, J. N., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30110-8 · Cited by 58
Politch, J. A., Cu‐Uvin, S., Moench, T. R., Tashima, K. T., Marathe, J. G., Guthrie, K. M., Cabral, H., Nyhuis, T. J., Brennan, M. B., Zeitlin, L., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003495 · Cited by 54
Social protection: potential for improving HIV outcomes among adolescents
Cluver, L., Hodes, R., Sherr, L., Orkin, F. M., Meinck, F., Lim, P., Ah, K., Winder-Rossi, N., Wolfe, J., & Vicari, M. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.7.20260 · Cited by 56
Yun, K., Xu, J., Zhang, J., Li, J., Hu, Q., Chu, Z., Jiang, Y., Geng, W., Shang, H., & Wang, N. (2017) · Sexually Transmitted Infections · doi:10.1136/sextrans-2017-053217 · Cited by 53
Montgomery, E., Atujuna, M., Krogstad, E. A., Hartmann, M., Ndwayana, S., O’Rourke, S., Bekker, L., van der Straten, A., & Minnis, A. M. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001960 · Cited by 53
Chemsex is not a barrier to self-reported daily PrEP adherence among PROUD study participants
O’Halloran, C., Rice, B. D., White, E., Desai, M., Dunn, D. T., McCormack, S., Sullivan, A. K., White, D., McOwan, A., & Gafos, M. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.10.007 · Cited by 53
Noguchi, L., Richardson, B. A., Baeten, J. M., Hillier, S. L., Balkus, J. E., Chirenje, Z. M., Bunge, K. E., Gita Ramjee, H., Nair, G., Palanee‐Phillips, T., et al. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00058-2 · Cited by 52
Mehrotra, M., Glidden, D. V., McMahan, V., Amico, K. R., Hosek, S., Defechereux, P. A., Mayer, K. H., Veloso, V. G., Bekker, L., Avelino‐Silva, V. I., et al. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1415-9 · Cited by 56
Baker, Z. G., Javanbakht, M., Mierzwa, S., Pavel, C., Lally, M., Zimet, G. D., & Gorbach, P. M. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1958-4 · Cited by 54
Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review
Tan, D. H. S., Senn, H., Sharma, M., & Wilton, J. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s50025 · Cited by 51
Walensky, R. P., Wheatley, M. M., Bekker, L., Parker, R. A., Wood, R., Resch, S., Horstman, N. K., Freedberg, K. A., & Paltiel, A. D. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv523 · Cited by 51
van der Straten, A., Brown, E. R., Marrazzo, J. M., Chirenje, M., Liu, K., Gomez, K., Marzinke, M. A., Piper, J. M., Hendrix, C. W., & on behalf of the MTN‐003 VOICE Protocol Team for the Microbicide Trials Network (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.1.20642 · Cited by 51
Dimitrov, D., Mâsse, B. R., & Donnell, D. J. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000993 · Cited by 53
Bowring, A. L., Ampt, F. H., Schwartz, S., Stoove, M. A., Luchters, S. M. F., Baral, S., & Hellard, M. E. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25442 · Cited by 49
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States
Bernard, C. L., Brandeau, M. L., Humphreys, K. N., Bendavid, E., Holodniy, M., Weyant, C., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2634 · Cited by 52
Mirembe, B. G., Kelly, C. W., Mgodi, N. M., Greenspan, S. L., Dai, J. Y., Mayo, A., Piper, J. M., Akello, C. A., Kiweewa, F. M., Magure, T. M., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000858 · Cited by 52
Combination HIV prevention options for young women in Africa
Baxter, C., & Karim, S. S. A. (2016) · African Journal of AIDS Research · doi:10.2989/16085906.2016.1196224 · Cited by 53
Hargreaves, J., Stangl, A. L., Bond, V. A., Hoddinott, G., Krishnaratne, S., Mathema, H., Moyo, M., Viljoen, L., Brady, L., Sievwright, K. M., et al. (2016) · Health Policy and Planning · doi:10.1093/heapol/czw071 · Cited by 50
Wright, E., Grulich, A. E., Roy, K., Boyd, M. A., Cornelisse, V. J., Russell, D. B., O’Donnell, D., Whittaker, B., Crooks, L., & Zablotska, I. (2018) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30260-0 · Cited by 51
Preparing for long‐acting PrEP delivery: building on lessons from oral PrEP
Celum, C., Grinsztejn, B. G. J., & Ngure, K. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26103 · Cited by 51
Hartmann, M., McConnell, M. A., Bekker, L., Celum, C., Bennie, T., Zuma, J., & van der Straten, A. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2044-2 · Cited by 49
Treatment and prevention of HIV infection with long-acting antiretrovirals
Benítez‐Gutiérrez, L., Soriano, V., Requena, S., Arias, A., Barreiro, P., & de Mendoza, C. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1453805 · Cited by 50
Hightow‐Weidman, L., Muessig, K. E., Rosenberg, E. S., Sanchez, T., LeGrand, S., Gravens, L., & Sullivan, P. S. (2018) · JMIR Research Protocols · doi:10.2196/10365 · Cited by 47
Gray, G., Mngadi, K. T., Lavreys, L., Nijs, S., Gilbert, P. B., Hural, J., Hyrien, O., Juraska, M., Luedtke, A. R., Mann, P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00358-x · Cited by 48
HIV preexposure prophylaxis for adolescents and young adults
Allen, E. B., Gordon, A. R., Krakower, D., & Hsu, K. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000512 · Cited by 48
Fonsart, J., Saragosti, S., Taouk, M., Peytavin, G., Bushman, L. R., Charreau, I., Hance, A. J., Goldwirt, L., Morel, S., Mammano, F., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw412 · Cited by 50
Mandal, S., Prathipati, P. K., Kang, G., Zhou, Y., Yuan, Z., Fan, W., Li, Q., & Destache, C. J. (2016) · AIDS · doi:10.1097/qad.0000000000001349 · Cited by 47
Ngure, K., Ortblad, K. F., Mogere, P., Bardon, A., Thomas, K. K., Mangale, D. I., Kiptinness, C., Gakuo, S., Mbaire, S., Nyokabi, J., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00126-6 · Cited by 47
Gulick, R. M., Wilkin, T. J., Chen, Y. Q., Landovitz, R. J., Amico, K. R., Young, A., Richardson, P., Marzinke, M. A., Hendrix, C. W., Eshleman, S. H., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw525 · Cited by 51
Velloza, J., & Heffron, R. A. (2017) · Current HIV/AIDS Reports · doi:10.1007/s11904-017-0362-z · Cited by 47
No. 354-Canadian HIV Pregnancy Planning Guidelines
Loutfy, M. R., Kennedy, V. L., Poliquin, V., Dzineku, F., Dean, N. L., Margolese, S. L., Symington, A. L., Money, D., Hamilton, S., Conway, T., et al. (2017) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2017.06.033 · Cited by 45
for the MTN-020/ASPIRE Team, Roberts, S. T., Nair, G., Baeten, J. M., Palanee‐Phillips, T., Schwartz, K. D., Reddy, K., Kabwigu, S., Kiweewa, F. M., Govender, V., et al. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02707-1 · Cited by 46
Oral preexposure prophylaxis continuation, measurement and reporting
Stankevitz, K., Grant, H., Lloyd, J., Gomez, G. B., Kripke, K. E., Torjesen, K., Ong, J. J., & Terris‐Prestholt, F. (2020) · AIDS · doi:10.1097/qad.0000000000002598 · Cited by 44
Felsher, M. A., Ziegler, E., Amico, K. R., Carrico, A. W., Coleman, J., & Roth, A. M. (2021) · Social Science & Medicine · doi:10.1016/j.socscimed.2021.113809 · Cited by 46
Thurman, A. R., Schwartz, J. L., Cottrell, M. L., Brache, V., Chen, B. A., Cochón, L., Ju, S., McGowan, I., Rooney, J. F., McCallister, S. H., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100893 · Cited by 46
Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention
Mugwanya, K. K., & Baeten, J. M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1128412 · Cited by 45
Mugwanya, K. K., Baeten, J. M., Celum, C., Donnell, D. J., Nickolas, T. L., Mugo, N., Branch, A. D., Tappero, J. W., Kiarie, J. N., Ronald, A., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw125 · Cited by 45
van der Straten, A., Shapley‐Quinn, M. K., Reddy, K., Cheng, H., Etima, J., Woeber, K., Musara, P., Palanee-Phillips, T., Baeten, J. M., Montgomery, E., et al. (2017) · AIDS Patient Care and STDs · doi:10.1089/apc.2017.0075 · Cited by 44
Kambutse, I., Igiraneza, G., & Ogbuagu, O. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207650 · Cited by 45
Shapley‐Quinn, M. K., Manenzhe, K. N., Agot, K. E., Minnis, A. M., & van der Straten, A. (2019) · International Journal of Women s Health · doi:10.2147/ijwh.s185712 · Cited by 45
Topical Microbicides in HIV Prevention: State of the Promise
Baeten, J. M., Hendrix, C. W., & Hillier, S. L. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-090518-093731 · Cited by 46
Lancaster, K. E., Lungu, T., Bula, A. K., Shea, J., Shoben, A. B., Hosseinipour, M. C., Kohler, R. E., Hoffman, I., Go, V. F.-L., Golin, C. E., et al. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02705-3 · Cited by 45
Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate
Simpson, S. M., Widanapathirana, L., Su, J. T., Sung, S., Watrous, D., Qiu, J., Pearson, E. K., Evanoff, A., Karunakaran, D., Chacon, J. E., et al. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-2777-2 · Cited by 45
Liu, A., Laborde, N. D., Coleman, K., Vittinghoff, E., Gonzalez, R., Wilde, G., Thorne, A. L., Ikeguchi, E., Shafner, L., Sunshine, L., et al. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-03054-2 · Cited by 45
Tapsoba, J. D. D., Cover, J., Obong’o, C. O., Brady, M., Cressey, T. R., Mori, K., Okomo, G. O., Kariithi, E., Obanda, R., Oluoch-Madiang, D., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004097 · Cited by 44
Lade, J. M., To, E. E., Hendrix, C. W., & Bumpus, N. N. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.07.008 · Cited by 44
Keller, M. J., Wood, L., Billingsley, J. M., Ray, L., Goymer, J., Sinclair, S., McGinn, A. P., Marzinke, M. A., Frank, B., Srinivasan, S., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30145-6 · Cited by 44
Mgodi, N. M., Takuva, S. G., Edupuganti, S., Karuna, S., Andrew, P., Lazarus, E. M., Garnett, P., Shava, E., Mukwekwerere, P. G., Kochar, N. K., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002649 · Cited by 44
Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study
Dai, J. Y., Hendrix, C. W., Richardson, B. A., Kelly, C., Marzinke, M. A., Chirenje, Z. M., Marrazzo, J. M., & Brown, E. R. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv333 · Cited by 43
Mandal, S., Kang, G., Prathipati, P. K., Zhou, Y., Fan, W., Li, Q., & Destache, C. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.027 · Cited by 43
Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections
Tyo, K. M., Lasnik, A. B., Zhang, L., Mahmoud, M. Y., Jenson, A. B., Fuqua, J. L., Palmer, K. E., & Steinbach-Rankins, J. M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.006 · Cited by 43
Sarr, M., Gueye, D. M., Mboup, A., Diouf, O., Bao, M. D. B., Ndiaye, A. J. S., Ndiaye, B., Hawes, S. E., Tousset, E., Diallo, A., et al. (2020) · International Journal of STD & AIDS · doi:10.1177/0956462420943704 · Cited by 43
Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use
Ustianowski, A., & Arends, J. E. (2015) · Infectious Diseases and Therapy · doi:10.1007/s40121-015-0070-1 · Cited by 43
Recent Advances in the Excipients Used in Modified Release Vaginal Formulations
Dedeloudi, A., Siamidi, A., Pavlou, P., & Vlachou, M. (2022) · Materials · doi:10.3390/ma15010327 · Cited by 42
Prasitsuebsai, W., Kerr, S. J., Truong, K. H., Ananworanich, J., Chau, V., Nguyen, L. V., Kurniati, N., Kosalaraksa, P., Sudjaritruk, T., Chokephaibulkit, K., et al. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0111 · Cited by 42
Long-acting rilpivirine for HIV prevention
Jackson, A., & McGowan, I. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000160 · Cited by 42
Price, J. T., Wheeler, S. B., Stranix‐Chibanda, L., Hosek, S., Watts, D. H., Siberry, G. K., Spiegel, H. M. L., Stringer, J. S. A., & Chi, B. H. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001063 · Cited by 42
Ogbuagu, O. E., Marshall, B. D. L., Tiberio, P. J., Ogunbajo, A., Barakat, L., Montgomery, M. C., Almonte, A. A., Wray, T. B., Williams, E. C., Edelman, E. J., et al. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2260-9 · Cited by 42
Markowitz, M. H., Gettie, A., Bernard, L. S., Andrews, C. D., Mohri, H., Horowitz, A., Grasperge, B. F., Blanchard, J., Niu, T., Sun, L. Z., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz271 · Cited by 42
Bollinger, R. C., Thio, C. L., Sulkowski, M., McKenzie‐White, J., Thomas, D. L., & Flexner, C. W. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30342-x · Cited by 42
Scorgie, F., Khoza, N., Baron, D., Lees, S. S., Harvey, S. E., Ramskin, L., Stangl, A. L., Colombini, M., Mashauri, E., Delany‐Moretlwe, S., et al. (2020) · Culture Health & Sexuality · doi:10.1080/13691058.2019.1703041 · Cited by 45
Bhardwaj, S., Carter, B., Aarons, G. A., & Chi, B. H. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-015-0260-1 · Cited by 42
Women-specific routes of administration for drugs: A critical overview
das Neves, J., Notario-Pérez, F., & Sarmento, B. F. C. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113865 · Cited by 44
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251
Andrews, C. D., Bernard, L. S., Poon, A. Y., Mohri, H., Gettie, N., Spreen, W. R., Gettie, A., Russell‐Lodrigue, K., Blanchard, J., Hong, Z., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001343 · Cited by 41
Trajectories of PrEP Adherence Among Young Women Aged 16 to 25 in Cape Town, South Africa
Stoner, M. C. D., Rucinski, K. B., Giovenco, D., Gill, K., Morton, J. F., Bekker, L., Celum, C., & van der Straten, A. (2021) · AIDS and Behavior · doi:10.1007/s10461-020-03134-3 · Cited by 41
ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions
Olesen, R., Swanson, M. D., Kovářová, M., Nochi, T., Chateau, M., Honeycutt, J. B., Long, J. M., Denton, P. W., Hudgens, M. G., Richardson, A., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci64212 · Cited by 39
Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study
For the iPrEx Study Team, Amico, K. R., Mehrotra, M., Avelino‐Silva, V. I., McMahan, V., Veloso, V. G., Anderson, P. L., Guanira, J. V., & Grant, R. M. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1360-7 · Cited by 39
Kinuthia, J., Richardson, B. A., Drake, A. L., Matemo, D. N., Unger, J. A., McClelland, R. S., & John-Stewart, G. C. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001225 · Cited by 40
Kuteesa, M. O., Quaife, M., Biraro, S., Katumba, K. R., Seeley, J., Kamali, A., & Nakanjako, D. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02418-7 · Cited by 38
Hannaford, A., Arens, Y., & Koenig, H. C. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s248696 · Cited by 42
Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis
Grant, R. M., Sevelius, J. M., Guanira, J. V., Aguilar, J. V., Chariyalertsak, S., & Deutsch, M. B. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001090 · Cited by 43
Friedland, B., Hoesley, C. J., Plagianos, M. G., Hoskin, E. K., Zhang, S., Teleshova, N., Alami, M., Novak, L., Kleinbeck, K., Katzen, L. L., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001136 · Cited by 39
Browne, E. N., Montgomery, E., Mansfield, C. A., Boeri, M., Mange, B., Beksinska, M. E., Schwartz, J. L., Clark, M. R., Doncel, G. F., Smit, J. A., et al. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02715-1 · Cited by 39
Lachowsky, N. J., Lin, S. Y., Hull, M., Cui, Z., Sereda, P., Jollimore, J., Rich, A. J., Montaner, J. S. G., Roth, E. A., Hogg, R. S., et al. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1319-8 · Cited by 38
Wand, H. C., Reddy, T., Naidoo, S., Moonsamy, S., Siva, S. S., Morar, N. S., & Gita Ramjee, H. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1785-7 · Cited by 38
Livant, E., Heaps, A., Kelly, C., Maharaj, R., Samsunder, N., Nhlangulela, L., Karugaba, P., Panchia, R., Marrazzo, J. M., Chirenje, Z. M., et al. (2017) · Journal of Clinical Virology · doi:10.1016/j.jcv.2017.06.006 · Cited by 38
Koss, C. A., Ayieko, J., Mwangwa, F., Owaraganise, A., Kwarisiima, D., Balzer, L. B., Plenty, A., Sang, N., Kabami, J., Ruel, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy390 · Cited by 38
Lal, M., Lai, M., Ugaonkar, S. R., Wesenberg, A., Kizima, L., Rodríguez, A., Levendosky, K., Mizenina, O. A., Fernández-Romero, J. A., & Zydowsky, T. M. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.06.002 · Cited by 38
Using discrete choice experiments to inform the design of complex interventions
The VMMC study team, Terris‐Prestholt, F., Neke, N. M., Grund, J. M., Plotkin, M., Kuringe, E., Osaki, H., Ong, J. J., Tucker, J. D., Mshana, G. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3186-x · Cited by 38
Balkus, J. E., Nair, G., Montgomery, E., Mishra, A., Palanee‐Phillips, T., Gita Ramjee, H., Panchia, R., Selepe, P., Richardson, B. A., Chirenje, Z. M., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000715 · Cited by 38
Adherence and the Lie in a HIV Prevention Clinical Trial
Stadler, J., Scorgie, F., van der Straten, A., & Saethre, E. J. (2015) · Medical Anthropology · doi:10.1080/01459740.2015.1116528 · Cited by 37
Promises and challenges: cabotegravir for preexposure prophylaxis
Spinelli, M. A., Grinsztejn, B. G. J., & Landovitz, R. J. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000733 · Cited by 37
Taneva, E., Crooker, K., Park, S. H., Su, J. T., Ott, A. K., Cheshenko, N., Szleifer, I. G., Kiser, P. F., Frank, B., Mesquita, P. M. M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02793-15 · Cited by 37
Nondaily preexposure prophylaxis for HIV prevention
Anderson, P. L., Garcia-Lerma, J. G., & Heneine, W. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000213 · Cited by 36
Chetty, T., Vandormael, A. M., Thorne, C., & Coutsoudis, A. (2017) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-017-1421-6 · Cited by 37
Giovenco, D., Pettifor, A. E., MacPhail, C. L., Kahn, K., Wagner, R. G., Piwowar‐Manning, E., Wang, J., & Hughes, J. P. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25359 · Cited by 37
Becquet, V., Nouaman, M., Plazy, M., Masumbuko, J.-M., Anoma, C., Soh, K., Danel, C., Eholié, S. P., & Larmarange, J. (2020) · BMJ Open · doi:10.1136/bmjopen-2018-028508 · Cited by 40
Pretorius, C., Schnure, M., Dent, J., Glaubius, R. L., Mahiané, G., Hamilton, M. P., Reidy, M., Matse, S., Njeuhmeli, E., Castor, D., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25451 · Cited by 35
Metadata
- Authors
- Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
- Affiliations
- University of California, San Francisco (US)
- Harborview Medical Center (US)
- Family Health International 360 (US)
- University of Zimbabwe (ZW)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of Pittsburgh (US)
- Johns Hopkins University (US)
- South African Medical Research Council (ZA)
- National Institutes of Health (US)
- Eastern Virginia Medical School (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-05
- Volume
- 372
- Issue
- 6
- Pages
- 509-518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4341965
- OpenAlex
- W2044369525
- Cited by
- 1,296
- References
- 19
- Citations by year
- 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
- FWCI
- 147.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
- MeSH terms
- Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
